The effectiveness of Satureja khuzistanica against cancerous cells

AUTHORS

Abdolhossein Rustaiyan

Prof.of Organic Chemistry. Department of Chemistry, Science & Research Branch, Islamic Azad University, Tehran, Iran.

1. Introduction
Cancer is a growing health problem around the world and has been reported as the second main cause of death after heart diseases [1]. The use of effective drugs with low toxicity and minor environmental impacts are of high significance for the prevention and treatment of the disease. As such, natural products play a vital role in preventing and treating cancer. Currently, a significant number of anti-tumor agents that are used in clinics are of a natural origin [2]. Therefore, the use of herbs as natural drugs can be of great help to solve this problem.
Satureja khuzistanica is an endemic plant of Iran with a wide distribution in the southern part of the country. It is well-known for its therapeutic value as an analgesic and antiseptic in folk medicine [3,4]. The genus of Satureja belongs to the family of Lamiaceae as a subfamily of Nepetoideae and the tribe of Mentheae [5] that the composition of the essential oil of This genus has been explored in different researchers [6-11].
Given the wide application of Satureja khuzistanica, an exploration of chemical compounds found in extracts of this plant to identify its bioactive compounds and standardization of ducts and its quality control as a pharmaceutical raw material is high importance. The phytochemical profile of nonvolatile part of plant extract has been explored in a few reports [12-14], where the chemical composition of the essential oil aerial parts of S. khuzistanica has been investigated very well. The main component of this plant is  an oxygenated monoterpene named carvacrol (natural isopropyl cresol / 5-isopropyl-2-methyl phenol(  [15-17]. This phenolic monoterpene found in most of the essential oils of medicinal and aromatic plants and has received a lot of attention on account of its useful biological activities.
Tansu Koparal et al., (2003) studied the effects of carvacrol on non-small cell carcinoma (NSCLC) A549. The effects of carvacrol on cell morphology, apoptosis, and total protein amount on selected cells were evaluated by incubation of various concentrations of carvacrol in DMSO for 24 h. As carvacrol was applied to A549 cell line, an increased dose of carvacrol induced a decrease in cell number, degeneration of cell morphology, and a decrease in total protein level. Light microscopy techniques were used to examine cells  induced changes in cell morphology by carvacrol. Afterwards, the cells that were treated using carvacrol  detached from the disk, with cell rounding, cytoplasmic blebbing, and irregularity in shape. The results also showed that carvacrol is a very strong inhibitor of cell growth in A549 cell line [18].
Zerrin et al., (2011) examined the impact of apoptotic carvacrol in H-RAS and N-RAS transformed CO25 cells and carvacrol ability as a chemotherapeutic medicine. The results showed that carvacrol has cytotoxic effects on the two cell lines in terms of time and concentration [19].
Rizvi et al., (2011) studied the carvacrol cytotoxic effects on cervical cancer (Hela & Sitla cells). Carvacrol cytotoxic effects were also studied separately using MTT and LDH techniques. Apoptosis was also measured using the DNA cleavage test. It was found that carvacrol cytotoxic effects on Hela and Sitla cells in 50 lc out of 50 mg/l. The dying cells displayed apoptotic features such as DNA cleavage. The results also illustrated carvacrol cytotoxic effects on cervical cancer cells. IC50 values were measured for 0.04 mg/mL 5RP7 and 0.1 mg/mL CO25 cell lines. Carvacrol, depending on the IC50 values, can also induce morphological changes on both cell types.
Phosphatidylserine localisation mobility was detected using flow cytometry only on 5RP7 cells. DNA laddering as the late apoptotic determinant was also found on H-ras transformed cells but not on N-ras transformed cells at a concentration of IC50 and lower values. This may show that the sensitivity of H-ras transformed a cell to carvacrol is greater than that of N-RAS-transformed cells. It was also found that carvacrol can be employed as anti-cancer medication for its apoptotic effects on cancer treatment [20]. The cytotoxic effects of six monoterpenes,carvacrol, thymol, carveol, carvone, eugenol, and isopulegol plus their molecular mechanisms were compared by Zyad et al., (2011). A comparison of the in vitro antitumor activity of the tested products against five tumor cell lines suggested that the carvacrol is the most cytotoxic monoterpene. In addition, the assessment of eventual synergistic effects of the six natural monoterpenes with two anticancer drugs indicated a significant level of synergy among them (P < 5%). The flow cytometry after DNA staining was used to assess the effects of the tested products on cell cycle progression with the aim of determining the molecular mechanisms behind their cytotoxic activity. It was found that carvacrol and carveol stopped the cell cycle progression in S phase, while thymol and isopulegol stopped it in G0/G1 phase. In contrast, carvone and eugenol were shown to have no impact on cell cycles when the used tumors were P-815, K-562, CEM, MCF-7, and MCF-7 gem [21]. 
Arunasree et al., (2011) explored carvacrol anti-proliferative effects on human metastatic breast cancer cell line MDA-MB 231 and determined the basic molecular mechanisms involved in its activity. In addition, carvacrol-induced apoptosis was determined using various assays like MTT assay, Annexin V, mitochondrial membrane potential assay, multi-caspase activation assay, and cell cycle analysis by flow cytometer. The authors also examined the cleavage of PARP, cytochrome c release, and modulation of Bax and Bcl2 ratio using Western blot analysis. Carvacrol-induced apoptosis was observed in MDA-MB 231 cells dose-dependently at an IC50 of 100 mM with a decrease in the mitochondrial membrane potential of the cells, inducing the release of cytochrome c from mitochondria, caspase activation, and cleavage of PARP[22].
In another study, Zhuang et al., (2012) explored anti-proliferative and pro-apoptotic effects of carvacrol on human hepatocellular carcinoma cell line HepG-2. Carvacrol was found to inhibit HepG2 cell growth by inducing apoptosis as shown by the results of Hoechst 33258 stain and Flow cytometric (FCM) analysis. In addition, the incubation of HepG2 cells using carvacrol for 24 h caused apoptosis by activating caspase-3, cleavage of PARP, and decreased Bcl-2 gene expression. It was also shown that a substantial portion of carvacrol treated cells died as a consequence of an apoptotic pathway in HepG2 cells. Besides, carvacrol selectively was shown to modify the phosphorylation state of members of the MAPK superfamily, decrease phosphorylation of ERK1/2 significantly in a dose-dependent manner, and activate phosphorylation of p38 but it had no impact on JNK MAPK phosphorylation. It was also shown that carvacrol might induce apoptosis via direct activation of the mitochondrial pathway. The mitogen-activated protein kinase pathway may also play a significant role in the antitumor effect of carvacrol. For the first time, it was noted that the biological activity of carvacrol in HepG2 cells might result in more development of carvacrol for liver disease therapy[23].
Chung-Ren et al., (2013) studied the effect of carvacrol on cytosolic free Ca2+ concentrations ([Ca2+]i), cell viability, and apoptosis in OC2 human oral cancer cells. It was shown that the natural essential oil carvacrol-induced Ca2+ releases from the endoplasmic reticulum in a PLC- and PKC-dependent manner and also causes Ca2+ entry through nonstore- operated Ca2+ channels in OC2 human oral cancer cells. In addition, it caused carvacrol-induced apoptosis that activates ROS and caspase-3 [24].
Pichardo et al., (2014) examined the cytotoxicity and morphological effects as induced by carvacrol and thymol on the human cell line Caco-2. Cytotoxicity endpoints assayed (total protein content, neutral red uptake, and the tetrazolium salt reduction) and the annexin/propidium iodide staining showed that carvacrol and the mixture carvacrol/thymol induced toxic effects. A morphological study was also performed in order to determine the ultrastructural cellular damages caused by these substances. The main morphological modifications were vacuolated cytoplasm, altered organelles, and finally cell death. However, no cytotoxic effects were seen for thymol at any concentration level and exposure time. Ultrastructural changes supported cellular damages such as lipid degeneration, mitochondrial damage, nucleolar segregation, and apoptosis[25].
Cytotoxicity and pro-apoptotic activity of carvacrol on human breast cancer cell line MCF-7 were assessed by Ayaz Ahmad et al., (2014). Cytotoxic effects of carvacrol were measured by MTT and LDH assays and induction of apoptotic was analyzed by expressional analysis of anti- and pro-apoptotic regulatory genes by reverse transcriptase PCR and DNA cleavage assays. The researchers showed that the carvacrol cytotoxicity against MCF-7 cancer cells was in a dose-dependent manner at 24 and 48 h time points (p < 0.05). in addition, IC50 of carvacrol at 48 h time point was 244.7 ±0.71 μM. It was also noted that carvacrol treated MCF-7 cells stimulated apoptosis through p53 dependent and Bcl-2/Bax pathway. It was also shown that carvacrol treatment induces caspase-3, -9, and -6 enzymes gene expression and genomic DNA cleavages [26].
Aydin (2014) conducted a study to assess in vitro antiproliferative and/or cytotoxic properties (by3-(4,5 dimetylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) test), genotoxic damage potentials (by single cell gel electrophoresis (SCGE) or Comet assay), and antioxidant activities (using total antioxidant capacity (TAC) and total oxidative stress (TOS) analysis) of CVC in vitro. Dose (0–400 mg/L) dependent effects of CVC were tested on both cultured primary rat neurons and N2a neuroblastoma cells. MTT assay results showed significant (p<0.05) decreases in cell proliferation rates in both cell types when treated with CVC at 200 and 400 mg/L. In contrast, the mean values of the total scores of cells supporting DNA damage (for comet assay) was not significantly different from the control values for both cells (p[0.05). In addition, it was noted that 10, 25, and 50 mg/L of CVC treatment increased TAC levels in cultured primary rat neurons but not in the N2a cell line. Nevertheless, CVC treatments increased TOS levels in cultured primary rat neurons at only 400 mg/L while they increased TOS levels in N2a neuroblastoma cells at 200 and 400 mg/L [27]. The present findings suggest that CVC could be a source of antioxidant and chemopreventive activities to be studied on cancer diseases.
2. Discussion
Cells in the carvacrol treatment show significant morphological variations such as cell shrinkage with rounding of cells and formation of membrane blebs characteristic of apoptosis as indicated by microscopic studies [28] in non-small lung cancer cells A549 treated by carvacrol and a study by Arunasree [22] in human metastatic breast cancer cell line MDA-MB 231. One of the biochemical characteristics of apoptotic cells is that cell surface markers achieved by flip-flop movement of the phosphatidylserine are expressed from inner membrane to the outer membrane of the plasma membrane [29].Annexin V as a recombinant phosphatidylserine-binding protein interacts strongly and specifically with phosphatidylserine residues and can be used for apoptosis detection [30].
Results from Annexin V assay using flow cytometer showed a dose-dependent increase in the Annexin V positive cells, which indicated induction of apoptosis by carvacrol [22]. However, the loss of DNA content is a typical distinguishing feature of apoptosis and staining of the cell with Propidium iodide and analyzing by flow cytometer would be useful in evaluating the cell viability. Consequently, flow cytometric analysis of carvacrol-treated cells was performed [31,32] and it was found the increase of sub G0/G1 phase (apoptotic peak) of the cell cycle and a decrease of cells at S phase in a concentration-dependent manner which support the induction of apoptosis and inhibition of DNA synthesis in S phase.
Carvacrol induced cytochrome c release from mitochondria and activation of caspases. A loss of mitochondrial membrane potential (DcM) shows the loss of cell viability as it reflects the pumping of protons across the inner membrane during processes of electron transport and oxidative phosphorylation that drives the conversion of ADP to ATP [22]. DcM in this study was measured using flow cytometer. The results demonstrated a dose-dependent decrease in the membrane potential and consequently, a dose-dependent increase in the percent apoptotic cells . A decrease in DcM changes the membrane stability, and it leads to the release of mitochondrial apoptosis initiation factors (AIFs), cytochrome c, and the apoptosis protease-activating factor (Apaf-1) into the cytosol. In the cytoplasm, cytochrome c is associated with caspase-9, Apaf- 1 and dATP to form the apoptosome complex [33], which in turn activates caspase- 9, -3 and -7. To further assess the apoptotic pathway, the release of cytochrome c from mitochondria into cytosol was analyzed using Western blot analysis in cytosolic fractions of carvacrol-treated cells. The results showed a dose-dependent increase in the levels of cytochrome c in the cytoplasm, pointing to the execution of apoptosis . In addition, the activation of caspases (multi-caspase activation) by cytochrome c was also studied by using flow cytometer, and the results clearly showed increased activity with an increase in the concentration of carvacrol.
Oligonucleosomal cleavage from DNA and PARP cleavage in response to carvacrol treatment were among other effects of carvacrol on cancerous cells. Another AIF, Caspase-Activated DNase (CAD), released from mitochondria, translocates into the nucleus, after getting cleaved by the activated caspase-3, and leads to oligonucleosomal cleavage of DNA into 180 bp fragments [30,31]. In a study conducted by Arunasree et al. (2011), the fragmentation of DNA into 180 bp ladder was found in carvacrol-treated MDAMB 231 cells confirming the apoptosis.
3. Results
As carvacrol is one of the main constituents of Satureja khuzistanica, it can be concluded that it shows strong anti-tumor effects. In this regard Mosayebi used  Satureja khuzistanica essential oil for  inhibit iNOS gene expression in Lipopolysaccharide-stimulated J774A.1 macrophage cell line .for this purpose  The effect of different doses of SKEO and carvacrol (0.004%, 0.008%, and 0.016%) on iNOS gene expression in normal and LPS-stimulated macrophage cell line was assessed by RT-PCR method and the  Results showed that  Both substances reduced the expression of iNOS gene in LPS-stimulated macrophage cell line in a dose and time-dependent manner, but SKEO was more potent than carvacrol.
So anti-inflammatory property of S. khuzistanica may be due to its effect on iNOS gene expression and reduction of NO as one of the mediators of inflammation [34]. Several reports are on the inhibitory effect of S. khuzistanica essential oil on cancer cell lines, lipid reduction, and healing points out that it can be effective as a combination , prevention, and treatment used.
ACKNOWLEDGMENT
The authors wish to thank Mohammad reza maneshi for His helpful assistance in preparing the manuscript.

References

  1. Bhalla Y, Gupta VK, Jaitak V. Anticancer activity of essential oils: a review. J Sci Food Agric. 2013; 93(15): 3643–3653.
  2. Efferth T, LiPCH, KonkimallaVSB and Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med. 2007; 13(8): 353–361.
  3. Zargari A. Medicinal Plants. 4th ed. Tehran University Publications; 1990: 42-45.
  4. Safarnavadeh T, Rastegarpanah M. Antioxidants and infertility treatment, the role of Satureja Khuzestanica: A mini-systematic review. Iranian Journal of Reproductive Medicine. 2011; 9(2): 61-70.
  5. Abdollahi M, Salehnia A, Mortazavi SHR, Ebrahimi E, Shafiee A, et al. Antioxidant, antidiabetic, antihyperlipidemic,reproduction stimulatory properties and safety of essential oil of Satureja Khuzestanica in rat in vivo:a toxicopharmacological study. Med Sci Monit. 2003; 9(9): 331-335.
  6. Habibi Z, Sedaghat S, Ghodrati T, Masoudi S and Rustaiyan A.  Volatile constituents of Satureja isophylla and S. cuneifolia from Iran. Chemistry of Natural Compounds. 2007; 43(6): 719-721.
  7. Malmir M, Gohari A.R, Saeidnia S and Silva O. A new bioactive monoterpene–flavonoid from Satureja khuzistanica. Fitoterapia.2015; 105: 107-112.
  8. Moghaddam F. M, Farimani M.M, Salahvarzi S and Amin G. Chemical Constituents of Dichloromethane Extract of Cultivated Satureja khuzistanica. Evidence-Based Complementary and Alternative Medicine. 2007; 4(1): 95-98.
  9. Rojas L. B, and Usubillaga A. Composition of the essential oil of Satureja brownei (SW.) Briq. from Venezuela. Flavour and fragrance journal. 2000; 15(1): 21-22.
  10. Rustaiyan A, Feizbakhsh A, Masoudi S and Ameri N. Comparison of the volatile oils of Satureja atropatana Bung. and Satureja mutica Fisch. et CA Mey. from Iran. Journal of Essential Oil Research. 2004; 16(6): 594-596.
  11. Senatore F, Urrunaga Soria E, Urrunaga Soria R, Della Porta G and De Feo V. Essential oils from two Peruvian Satureja species. Flavour and fragrance journal. 1998; 13(1): 1-4.  
  12. Davoodi M, Rustaiyan A, Ebrahimi S.N. Monoterpene Flavonoid from Aerial Parts of Satureja khuzistanica. Records of Natural Products. 2018; 12(2): 175-178.
  13. Moghaddam, F.M., Farimani, M.M., Salahvarzi, S., Amin, G., 2007. Chemical Constituents of Dichloromethane Extract of Cultivated Satureja khuzistanica. Evidence-Based Complementary and Alternative Medicine 4, 95-98.
  14. Malmir M, Gohari A.R., Saeidnia S, Silva O, 2015. A new bioactive monoterpene–flavonoid from Satureja khuzistanica. Fitoterapia 105, 107-112.
  15. Ghasemi Pirbalouti A, Moalem E, Yousefi Y, Malekpoor F, Yousef-Naanaie S. Influence of   Ecological Factors on Carvacrol Content of Satureja khuzestanica Jamzad. Jeobp. 2011; 14 (5): 630 - 638.
  16. Farsam H, Amanlou M, Radpour M R, Salehinia A N, Shafiee A. Composition of the essential oils of wild and cultivated Satureja khuzistanica Jamzad from Iran. Flavour Fragr. J. 2004; 19(4): 308–310.
  17. Saei-Dehkordi S, Fallah  A, Heidari-Nasirabadi M, Moradi  M. Chemical composition, antioxidative capacity and interactive antimicrobial potency of Satureja khuzestanica Jamzad essential oil and antimicrobial agents against selected food-related microorganisms. International Journal of Food Science and Technology. 2012; 47(8): 1579–1585.
  18. Tansu Koparal A, Zeytinoglu M. Effects of carvacrol on a human non-small cell lung cancer (NSCLC) cell line, A549. Cytotechnology. 2003; 43(1-3): 149–154.
  19. Zerrin INCESU, Gülşen , AKALIN. The effects of carvacrol on apoptosis of H-RAS and N-RAS transformaed cell lines. Turk J. Pharm. 2011; 8(2): 105-116.
  20. Mehdi  SJ, Ahmad  A, Irshad  M, Manzoor  N, Rizvi MMA. Cytotoxic effect of Carvacrol on human cervical cancer cells. Biology and Medicine. 2011; 3 (2): 307-312.
  21. Jaafari A, Tilaoui M, Ait Mouse AM, Ait M’bark L, Aboufatima R, et al. Comparative study of the antitumor effect of natural monoterpenes: relationship to cell cycle analysis. Revista Brasileira de Farmacognosia Brazilian Journal of Pharmacognosy. 2012; 22(3): 534-540.
  22. Arunasree  KM. Anti-proliferative effects of carvacrol on a human metastatic breast cancer cell line, MDA-MB 231. Phytomedicine. 2010; 17(8-9): 581–588.
  23. Yin QH, Yan FX, Zu XY, Wu YH, Wu XP, et al. Anti-proliferative and pro-apoptotic effect of carvacrol on human hepatocellular carcinoma cell line HepG-2. Cytotechnology. 2012; 64(1): 43–51.
  24. Liang WZ, Chou CT, Lu T, Chi CC, Tseng LL, et al. The mechanism of carvacrol-evoked [Ca2+]i rises and non-Ca2+-triggered cell death in OC2 human oral cancer cells. Toxicology. 2013; 7(303): 152– 161.
  25. Llana-Ruiz-Cabello M, Gutierrez-Praena D, Pichardo S, Moreno FJ, Maria Bermudez J, et al. Cytotoxicity and morphological effects induced by carvacrol and thymol on the human cell line Caco-2. Food and Chemical Toxicology. 2014; 64: 281–290.
  26. l-Fatlawi AA, Rahisuddin, Ahmad A. Cytotoxicity and pro-apoptotic activity of carvacrol on human breast cancer cell line MCF-7. World J Pharm Sci. 2014; 2(10): 1218-1223.
  27. Aydın E, Tu¨rkez  H, Keles MS. The effect of carvacrol on healthy neurons and N2a cancer cells: some biochemical, anticancerogenicity and genotoxicity studies. Cytotechnology. 2014; 66(1): 149–157.
  28. Koparal  AT, Zeytinoglu M. Effects of Carvacrol on a Human Non-Small Cell Lung Cancer (NSCLC) Cell Line, A549. Cytotechnology. 2003; 43(1-3): 149–154.  19
  29. L. Bratton D, A. Fadok D, Pichardo V, A. Richter D, M. Kailey J, et al. Appearance of Phosphatidylserine on Apoptotic Cells Requires Calcium-mediated Nonspecific Flip-Flop and Is Enhanced by Loss of the Aminophospholipid Translocase . The Journal of Biological Chemistry. 1997; 272(42): 26159-26165.
  30. Arur S,  Uche UE, Rezaul K, Fong M, Scranton V, et al. Annexin I is an endogenous ligand that mediates apoptotic cell engulfment. Dev Cell. 2003; 4(4): 587-98.
  31. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 1998; 391(6662): 43-50.
  32. Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature. 1998; 1;391(6662): 96-9.
  33. Chinnaiyan AM. The apoptosome: heart and soul of the cell death machine. Neoplasia. 1999; 1(1): 5-15.
  34. Jalalvand M, Shahsavari R, Sheikhian A, Mosayebi G. Satureja Khozestanica essential oil (SKEO) inhibits iNOS gene expression in Lipopolysaccharide-stimulated J774A.1 macrophage cell line. Life Science Journal. 2013; 10(2): 230-235.